Activation of NF-κB is involved in 6-hydroxydopamine—but not MPP+-induced dopaminergic neuronal cell death: its potential role as a survival determinant

Abstract

The nuclear factor-kappaB (NF-κB) family plays an important role in the control of the apoptotic response. Its activation has been demonstrated in both neurons and glial cells in many neurological disorders. In the present study, we specifically examined whether and to what extent NF-κB activation is involved in culture models of Parkinson’s disease following exposure of MN9D dopaminergic neuronal cells to 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-4-phenylpyridinium ion (MPP+). Both analysis by immunocytochemistry and of immunoblots revealed that NF-κB–p65 was translocated into the nuclei following 6-OHDA but not MPP+-treatment. A time-dependent activation of NF-κB induced by 6-OHDA but not MPP+ was also demonstrated by an electrophoretic mobility shift assay. A competition assay indicated that not only NF-κB–p65 but also –p50 is involved in 6-OHDA-induced NF-κB activity. Co-treatment with an antioxidant, N-acetyl-l-cysteine, blocked 6-OHDA-induced activation of NF-κB signaling. In the presence of an NF-κB inhibitor, pyrrolidine dithiocarbamate (PDTC), 6-OHDA-induced cell death was accelerated while PDTC did not affect MPP+-induced cell death. Our data may point to a drug-specific activation of NF-κB as a survival determinant for dopaminergic neurons.